

Mauro Biffi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704761/publications.pdf>

Version: 2024-02-01

30
papers

1,702
citations

687363

13
h-index

454955

30
g-index

30
all docs

30
docs citations

30
times ranked

2054
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative checklist to reduce the risk of cardiac implantable electronic device infections. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 262-269.	1.2	3
2	Vascular Accesses in Cardiac Stimulation and Electrophysiology: An Italian Survey Promoted by AIAC (Italian Association of Arrhythmias and Cardiac Pacing). Biology, 2022, 11, 265.	2.8	2
3	Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates. Nature Communications, 2022, 13, 2454.	12.8	11
4	Cum Grano Salis: Cardiac Sarcoidosis as a Perfect Mimic of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Cardiovascular Imaging, 2021, 14, e012355.	2.6	1
5	Mutations in MYBPC3 and MYH7 in Association with Brugada Type 1 ECG Pattern: Overlap between Brugada Syndrome and Hypertrophic Cardiomyopathy?. Neurology International, 2021, 11, 139-147.	0.5	5
6	Cardiac resynchronization therapy defibrillators in patients with permanent atrial fibrillation. ESC Heart Failure, 2021, , .	3.1	4
7	Left Ventricular Myocardial Noncompaction with Advanced Atrioventricular Conduction Disorder and Ventricular Arrhythmias in a Young Patient: Role of MIB1 Gene. Journal of Cardiovascular Development and Disease, 2021, 8, 109.	1.6	2
8	Intraprocedural PRAETORIAN score for early assessment of Sâ€CD implantation: A proofâ€ofâ€concept study. Journal of Cardiovascular Electrophysiology, 2021, 32, 3035-3041.	1.7	6
9	Pacing devices to treat bradycardia: current status and future perspectives. Expert Review of Medical Devices, 2021, 18, 161-177.	2.8	11
10	Safety of Omitting Defibrillation Efficacy Testing With Subcutaneous Defibrillators: A Propensity-Matched Case-Control Study. Circulation: Arrhythmia and Electrophysiology, 2021, 14, CIRCEP121010381.	4.8	5
11	Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced Exâ€Vivo and Inâ€Vivo Genetic Engineering. Molecular Therapy - Methods and Clinical Development, 2020, 19, 411-425.	4.1	21
12	The ECG Belt for CRT response trial: Design and clinical protocol. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1063-1071.	1.2	7
13	The role of atrial sensing for newâ€onset atrial arrhythmias diagnosis and management in singleâ€chamber implantable cardioverterâ€defibrillator recipients: Results from the THINGS registry. Journal of Cardiovascular Electrophysiology, 2020, 31, 846-853.	1.7	15
14	Diagnosis and management of subcutaneous implantable cardioverterâ€defibrillator infections based on process mapping. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 958-965.	1.2	8
15	Rateâ€responsive pacing and atrial high rate episodes in cardiac resynchronization therapy patients: Is low heart rate the key?. Clinical Cardiology, 2019, 42, 820-828.	1.8	8
16	Real-life outcome of implantable cardioverter-defibrillator and cardiac resynchronization defibrillator replacement/upgrade in a contemporary population: observations from the multicentre DECODE registry. Europace, 2019, 21, 1527-1536.	1.7	25
17	The neverâ€ending story of CIED infection prevention: Shall we WRAPâ€IT and go?. Journal of Cardiovascular Electrophysiology, 2019, 30, 1191-1196.	1.7	6
18	Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Science Translational Medicine, 2019, 11, .	12.4	65

#	ARTICLE	IF	CITATIONS
19	Successful defibrillation verification in subcutaneous implantable cardioverter-defibrillator recipients by low-energy shocks. <i>Clinical Cardiology</i> , 2019, 42, 612-617.	1.8	13
20	Is ventricular sensing always right, when it is left?. <i>Clinical Cardiology</i> , 2018, 41, 1238-1245.	1.8	11
21	Genome editing for scalable production of alloantigen-free lentiviral vectors for <i>in vivo</i> gene therapy. <i>EMBO Molecular Medicine</i> , 2017, 9, 1558-1573.	6.9	41
22	Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. <i>Cell</i> , 2016, 167, 219-232.e14.	28.9	363
23	VDR-dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D3. <i>Journal of Leukocyte Biology</i> , 2007, 81, 250-262.	3.3	55
24	Calcitriol derivatives with two different side chains at C-20. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 103, 277-281.	2.5	21
25	Transcript imaging of the development of human T helper cells using oligonucleotide arrays. <i>Nature Genetics</i> , 2000, 25, 96-101.	21.4	209
26	Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells. <i>Journal of Experimental Medicine</i> , 1997, 185, 825-832.	8.5	717
27	A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2011-2016.	6.4	30
28	Involvement of Multiple Protein Kinases in CD3-Mediated Activation of Human T Lymphocytes. <i>Cellular Immunology</i> , 1994, 153, 39-51.	3.0	11
29	Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. characterization of cells cultured <i>ex vivo</i> and their contribution to the <i>in vivo</i> immunomodulation. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 128-132.	4.2	10
30	Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells. <i>Cancer Immunology, Immunotherapy</i> , 1990, 32, 161-166.	4.2	16